Baird lowered the firm’s price target on Nevro to $19 from $23 and keeps a Neutral rating on the shares. The firm said its 2024 revenue guide bracketed CNS estimates at the upper-end, while better-than-anticipated adjusted- EBITDA guide was a brightspot.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVRO:
- Nevro Corp Enhances Board and Governance with New Director Appointment
- Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
- NVRO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Nevro price target lowered to $19 from $23 at Canaccord
- Nevro announces Carelon publication on new interventional pain management policy